Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Election/Restrictions
Applicant’s election without traverse of Group I and SEQ ID NO: 6 in the reply filed on 9/25/2026 is acknowledged.
Applicants elected species (i.e. SEQ ID NO: 6) was deemed to be free of the prior art. The search was extended to another species (i.e. SEQ ID NO: 8). As a result, claims 1 and 5-6 have been examined and claims 2-4 and 7-18 are withdrawn from consideration. While applicant’s elected species may read on one or more withdrawn claims, they have not been fully examined for patentability, and thus a determination of allowability cannot be made with respect to these claims at this time.
Status of the Claims
Claims 1-18 are pending in this application.
Claims 2-4 and 7-18 are withdrawn from consideration as being drawn to a non-elected species/invention.
Claims 1 and 5-6 are presently under consideration as being drawn to the elected species/invention.
Claim Objections
Claims 1 and 5 are objected to because of the following informalities: Claim 1 should be amended to recite “A polypeptide molecule any one of SEQ ID NOs: 6-8 and 10;or a polypeptide molecule having at least 90% sequence identity to any one of SEQ ID NOs: 6-8 and 10molecule of claim 1”. Appropriate correction is required.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1 and 5-6 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Claims 1 and 5-6 are directed to a product of nature. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception.
The rationale for this determination is explained below:
Instant claim 1 is drawn to polypeptide molecules comprising various sequences. It is noted that this rejection applies to the species examined (i.e. SEQ ID NO: 8).
Claims 5-6 are drawn to a composition comprising the polypeptide and a pharmaceutically acceptable carrier and/or excipient.
As evidenced by Galdes et al. (US 6884770), SEQ ID NO: 8 is a fragment of hedgehog (see SEQ ID NO: 10, columns 77-78).
The Office has prepared interim guidance (2014 Interim Guidance on Patent Subject Matter Eligibility) (Federal Register/Vol. 79, No. 241, Dec. 16, 2014) for use by USPTO personnel under 35 U.S.C. 101 in view of recent U.S. Supreme Court decisions. The 2014 Interim Eligibility Guidance supersedes the March 4, 2014 Process for Subject Matter Eligibility Analysis of Claims Reciting or Involving Laws of Nature/Natural Principles, Natural Phenomena, and/or Natural Products.
The current Interim Guidance provides subject eligibility test or products and processes (See Flow Chart, p. 74621):
Step 1: The instant claims are directed to a statutory patent-eligible subject matter category, a composition of matter.
Step 2A: The claims involve a judicial exception, a product of nature.
Specifically, the claims are drawn to a fragment of the naturally occurring protein hedgehog.
Step 2B: The claims do not recite additional elements that amount to significantly more that the judicial exception.
Markedly different characteristics can be expressed as the product's structure, function, and/or other properties and is evaluated based on what is recited in the claim. In accordance with this analysis, a product that is purified or isolated will be eligible when there is a resultant change in characteristics sufficient to show a marked difference from the products naturally occurring counterpart.
The Applicants have not shown a marked difference from the products naturally occurring counterpart.
Myriad clarified that not every change to a product will result in a marked difference, and that the mere recitation of particular words (e.g., “isolated”) in the claims does not automatically confer eligibility. Id. at 2119. See also Mayo, 132 S. Ct. at 1294 (eligibility does not “depend simply on the draftsman’s art”). The instant claims do not show any additional ingredients for the composition that imparts markedly different characteristic from any naturally occurring counterparts.
With respect to claims 5-6, “a pharmaceutically acceptable carrier” includes water, which is naturally occurring.
Therefore, the claims are drawn to a judicial exception and are considered patent ineligible.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1 and 5-6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Galdes et al. (US 6884770).
It is noted that in the requirement for restriction/Election filed on 8/5/2026, the Examiner requested the election of one specific polypeptide molecule by defining each and every amino acid. Applicant elected SEQ ID NO: 6. Thus, it is clear that claim 1 relates to a polypeptide molecule comprising either SEQ ID NO: 6 or SEQ ID NO: 7 or SEQ ID NO: 8 or SEQ ID NO: 10 or a sequence having at least 90% identity to any one of SEQ ID NO: 6-8 and 10.
Therefore, claim 1 has been interpreted as being drawn to “A polypeptide molecule any one of SEQ ID NOs: 6-8 and 10;or a polypeptide molecule having at least 90% sequence identity to any one of SEQ ID NOs: 6-8 and 10
With respect to claim 1, Galdes et al. teach SEQ ID NO: 10 (claim 1), which comprises instant SEQ ID NO: 8.
With respect to claims 5-6, Galdes et al. teach compositions comprising the polypeptide and a pharmaceutically acceptable carrier (column 49, lines 47-67).
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SERGIO COFFA Ph.D./
Primary Examiner
Art Unit 1658
/SERGIO COFFA/Primary Examiner, Art Unit 1658